The PanAM study: A multi-center, double-blinded, randomized, non-inferiority study of paracetamol versus non-steroidal anti-inflammatory drugs in treating acute musculoskeletal trauma

被引:9
|
作者
Ridderikhof M.L. [1 ]
Lirk P. [2 ]
Schep N.W. [3 ]
Hoeberichts A. [4 ]
Goddijn W.T. [1 ]
Luitse J.S.K. [1 ]
Kemper E.M. [5 ]
Dijkgraaf M.G. W. [6 ]
Hollmann M.W. [2 ]
Goslings J.C. [3 ]
机构
[1] Department of Emergency Medicine, Academic Medical Center, 1100 DD, Amsterdam
[2] Department of Anaesthesiology, Academic Medical Center, 1100 DD, Amsterdam
[3] Trauma Unit Department of Surgery, Academic Medical Center, 1100 DD, Amsterdam
[4] General Practice Health Care Center Gein, 1106 MH, Amsterdam
[5] Department of Pharmacy, Academic Medical Center, 1100 DD, Amsterdam
[6] Clinical Research Unit, Academic Medical Center, 1100 DD, Amsterdam
关键词
Analgesia; Anti-inflammatory agents; Contusions; Costs and cost analysis; Non-steroidal; Pain; Paracetamol/acetaminophen; Strains and sprains; Wounds and injuries;
D O I
10.1186/1471-227X-13-19
中图分类号
学科分类号
摘要
Background: Acute musculoskeletal trauma, including strains, sprains or contusions, occur frequently. Pain management is a crucial component of treatment. However, there is no convincing evidence which drug is superior in managing pain in these patients. The aim of the PanAM Study is to compare analgesic efficacy of three strategies of pain management: paracetamol, diclofenac, or a combination of both in patients with acute musculoskeletal trauma.Methods/design: The PanAM Study is a multi-center, double blind randomized controlled trial with non-inferiority design. Included are adult patients presenting to an academic, urban Emergency Department or to a General Practice with acute, blunt, traumatic limb injury. In total, 547 patients will be included using a predefined list of exclusion criteria, to be allocated by randomization to treatment with paracetamol + placebo diclofenac, diclofenac + placebo paracetamol or paracetamol + diclofenac. The hypothesis is that paracetamol will not be inferior to treatment with diclofenac, or the combination of both. Primary outcome will be between-group differences in decrease in pain, measured with Numerical Rating Scales at baseline and at 90 minutes after study drug administration. Secondary outcomes are Numerical Rating Scales at 30 and 60 minutes and measured frequently during three consecutive days after discharge; occurrence of adverse effects; patient satisfaction and an analysis of quality of life and cost-effectiveness. Recruitment started July 2013 and is expected to last a year.Discussion: With this multi-center randomized clinical trial we will investigate whether treatment with paracetamol alone is not inferior to diclofenac alone or a combination of both drugs in adult patients with acute musculoskeletal trauma. The main relevance of the trial is to demonstrate the benefits and risks of three commonly used treatment regimens for musculoskeletal trauma. Data that lead to the prevention of severe Non-Steroidal Anti-Inflammatory Drugs-related adverse effects might be gathered.Trial registration: Dutch Trial Register (http://www.trialregister.nl): NTR3982.EudraCT database (http://www.clinicaltrialsregister.eu): 201300038111. © 2013 Ridderikhof et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 50 条
  • [41] Heavy users of non-steroidal anti-inflammatory drugs: a nationwide prescription database study in Finland
    Helin-Salmivaara, A
    Klaukka, T
    Huupponen, R
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (5-6) : 477 - 482
  • [42] Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case–control study
    M C Bradley
    C M Hughes
    M M Cantwell
    G Napolitano
    L J Murray
    British Journal of Cancer, 2010, 102 : 1415 - 1421
  • [43] Electrochemical study of some non-steroidal anti-inflammatory drugs: solvent effect and antioxidant activity
    Fotios Tsopelas
    Maria Ochsenkühn-Petropoulou
    Nikos Zikos
    Eleni Spyropoulou
    Ioanna Andreadou
    Anna Tsantili-Kakoulidou
    Journal of Solid State Electrochemistry, 2011, 15 : 1099 - 1108
  • [44] Non-steroidal anti-inflammatory drugs among chronic kidney disease patients: an epidemiological study
    Samar Abd ElHafeez
    Reem Hegazy
    Yasmine Naga
    Iman Wahdan
    Sunny Sallam
    Journal of the Egyptian Public Health Association, 94
  • [45] Non-steroidal anti-inflammatory drugs among chronic kidney disease patients: an epidemiological study
    Abd ElHafeez, Samar
    Hegazy, Reem
    Naga, Yasmine
    Wahdan, Iman
    Sallam, Sunny
    JOURNAL OF THE EGYPTIAN PUBLIC HEALTH ASSOCIATION, 2019, 94 (01): : 1 - 8
  • [46] Non-steroidal anti-inflammatory drugs and perforated diverticular disease: a case-control study
    Goh, H
    Bourne, R
    ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND, 2002, 84 (02) : 93 - 96
  • [47] Measurement of Cyclooxygenase Inhibition in vivo: A Study of Two Non-Steroidal Anti-Inflammatory Drugs in Sheep
    Z. Cheng
    A. M. Nolan
    Q. A. McKellar
    Inflammation, 1998, 22 : 353 - 366
  • [48] Non-steroidal anti-inflammatory drugs for pain in hospice/palliative care: an international pharmacovigilance study
    McNeill, Richard
    Boland, Jason W.
    Wilcock, Andrew
    Sinnarajah, Aynharan
    Currow, David C.
    BMJ SUPPORTIVE & PALLIATIVE CARE, 2023, 13 (E3) : e1249 - e1257
  • [49] A STUDY OF THE RELATIVE HEPATOTOXICITY INVITRO OF THE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS IBUPROFEN, FLURBIPROFEN AND BUTIBUFEN
    CASTELL, JV
    LARRAURI, A
    GOMEZLECHON, MJ
    XENOBIOTICA, 1988, 18 (06) : 737 - 745
  • [50] Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses’ Health Study
    J. M. Jeter
    J. Han
    M. E. Martinez
    D. S. Alberts
    A. A. Qureshi
    D. Feskanich
    Cancer Causes & Control, 2012, 23 : 1451 - 1461